Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2021-01-29 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the issuance of new shares or equity-linked instruments.
2021-01-29 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders eligible to vote at an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it is a specific regulatory notification that does not fit into the other categories like dividend or share issuance, it is classified as a general regulatory filing.
2020-12-15 Korean
기타경영사항(특허권취득)(자율공시)(간질환 치료제(Therapeutic Agent For Liver Disorder))
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a liver disease treatment (Therapeutic Agent For Liver Disorder) by Aptabio. It details the patent name, content, holder, and utilization plan. Since it does not fit into specific categories like financial reports, board changes, or shareholder notifications, and is a regulatory disclosure of a corporate event, it falls under the general regulatory filing category.
2020-12-11 Korean
기타경영사항(특허권취득)(자율공시)(안질환 치료용 조성물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for an eye disease treatment composition by Aptabio. It details the patent name, content, owners, and utilization plans. Since this is a regulatory disclosure of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2020-12-09 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Aptabio Therapeutics Inc. covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial information, company overview, capital structure, and business operations, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the acquisition of shares by an executive (Seo Jong-nam) of AptaBio Co., Ltd. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents personal share transactions by a company director/executive.
2020-08-25 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.